In last trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 2.05 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $0.74 trading at $0.05 or 7.66% at ring of the bell on the day assigns it a market valuation of $137.40M. That closing price of NKTR’s stock is at a discount of -160.81% from its 52-week high price of $1.93 and is indicating a premium of 41.89% from its 52-week low price of $0.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.42 million shares which gives us an average trading volume of 2.41 million if we extend that period to 3-months.
For Nektar Therapeutics (NKTR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.18 in the current quarter.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Upright in the green during last session for gaining 7.66%, in the last five days NKTR remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $0.74 price level, adding 1.33% to its value on the day. Nektar Therapeutics’s shares saw a change of -20.61% in year-to-date performance and have moved 21.67% in past 5-day. Nektar Therapeutics (NASDAQ:NKTR) showed a performance of -11.82% in past 30-days. Number of shares sold short was 7.77 million shares which calculate 5.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18.5 to the stock, which implies a rise of 96.0% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -710.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -710.81% for stock’s current value.
Nektar Therapeutics (NKTR) estimates and forecasts
This year revenue growth is estimated to fall -35.13% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.92M for the same. And 8 analysts are in estimates of company making revenue of 16.03M in the next quarter. Company posted 21.64M and 23.49M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.49% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -13.65% while estimates for its earnings growth in next 5 years are of -15.48%.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders are in possession of 1.26% of company’s total shares while institution are holding 71.91 percent of that, with stock having share float percentage of 72.83%. Investors also watch the number of corporate investors in a company very closely, which is 71.91% institutions for Nektar Therapeutics that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at NKTR for having 17.88 million shares of worth $22.17 million. And as of 2024-06-30, it was holding 8.5599 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 15.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.2575 of outstanding shares, having a total worth of $18.79 million.
On the other hand, MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.65 shares of worth $4.91 million or 3.57% of the total outstanding shares. The later fund manager was in possession of 5.72 shares on Dec 31, 2024 , making its stake of worth around $4.23 million in the company or a holder of 3.08% of company’s stock.
